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A B S T R A C T
This paper aims to provide an overview of the current state of affairs on psychophysiological factors that
may explain the link between depression and adverse outcome in coronary artery disease (CAD)
patients. Factors discussed include heart rate variability, inﬂammation, platelet function, hypothala-
mus–pituitary–adrenal axis activity, serotonin metabolism and polyunsaturated fatty acids. Evidence
suggests the involvement of each of these factors in both depression and CAD, together contributing to
the prospective association between depression and cardiac outcome. Unfortunately, the involvement of
above factors has been evaluated mostly in isolation, despite their functional interrelations and
associations with behavioral factors. Moreover, there may be speciﬁc relations between individual
symptoms of depression and certain psychophysiological mechanisms, rather than with general
depression, further complicating the notion of depression as a cardiotoxic factor. The relatively
understudied complexity of the relation between depression and CAD may serve as an explanation for
the ﬁnding that depression treatment does not or barely affect cardiac outcome. Future studies should
focus on the network of psychophysiological (and behavioral) factors to elucidate their precise role and
timing in depressed cardiac patients.
 2009 Elsevier Ltd. All rights reserved.
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doi:10.1016/j.neubiorev.2009.11.025Depression and ischemic heart disease are the two strongest
contributors to the global burden of disease (Mathers and Loncar,
2006). Moreover, an intriguing and complex, bidirectional
association between psychological factors and heart disease has
been observed inwhich psychological factors act as risk factors for
heart disease and vice versa.Most research has focused on the role
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artery disease (CAD) have been studied as well, including stress,
anxiety, anger, and speciﬁc personality features, such as hostility
and Type D personality (Rozanski et al., 2005; Razzini et al., 2008;
Suls and Bunde, 2005). As most research has been done on the
psychophysiological correlates of depression in the context of
CAD, the focus of the current review will be on depression only.
Research to date has concentrated on the association between
depression following acute coronary syndromes (ACS) and its
subsequent association with cardiac disease progression and
cardiovascular events, such as myocardial infarction (MI), stroke,
chronic heart failure, or cardiac death (Barth et al., 2004; Van
Melle et al., 2004a).
The presence of depression following ACS is associated with a
twofold increased risk of fatal and nonfatal cardiac events. In
individuals without baseline CAD, major depression has been
related to the onset of a wide range of cardiovascular diseases (Van
der Kooy et al., 2007). In addition, depression following MI has
been associated with an average 2.0–2.5 increased risk of poor
cardiovascular outcome (Van Melle et al., 2004a). On the other
hand, it has become clear that heart disease is a risk factor for
depression, evidenced by at least threefold increased prevalence
rates (15–20% versus 5% in the general population) of major
depression following ACS (Thombs et al., 2006).
These ﬁndings warrant further research on the mechanisms
behind the association between depression and heart disease
(Berkman et al., 2003; Glassman et al., 2002; Lesperance et al.,
2007; Van Melle et al., 2007). It is possible that an incorrect or
incomplete understanding of the complex nature of the association
between heart disease and depression lies at the heart of the
failures of recent randomized trials showing only relativelymodest
improvements of depressive symptoms after antidepressive
treatment that did not translate into improved cardiac outcome.
Therefore, we set out to provide a review of the evidence on the
role of psychophysiological factors in explaining the link between
depression and adverse outcome in CAD patients. Earlier, in an
authorative overview, Carney and colleagues have identiﬁed lower
HRV, reﬂecting altered cardiac autonomic tone, increased platelet
aggregation, and inﬂammatory activation as possible factors
(Carney et al., 2002). In the present review, we will (1) examine
the current literature on these three factors, (2) add HPA axis
dysregulation, serotonin transmission, and polyunsaturated fatty
acids (PUFAs) as additional candidate psychophysiological factors,
(3) provide insight in the potential integration of the different
psychophysiological factors, and (4) discuss some ways of how to
proceed.
1. Psychophysiological factors
1.1. Heart rate variability
Heart rate variability (HRV), or the healthy beat-to-beat
variations in heart rate results from ﬂuctuations in autonomic
nervous system (ANS) activity at the sinus node, and is a non-
invasive marker of ANS activation of the heart. In CAD, ANS
imbalance is observed, indicated by vagal withdrawal and
increased sympathetic cardiac drive. This imbalance, favoring
sympathetic cardiac drive, is associated with tachycardia and a
reduction of total power in the spectral domain of HRV, resulting in
lower HRV than non-cardiac patients (Task force ESC and NASPE,
1996). Activation of the sympathetic Nervous System as reﬂected
by decreased HRV is related to the occurrence of life threatening
arrhythmias, particularly in patients with a low LVEF (La Rovere et
al., 2001). As a consequence, reduced HRV is predictive of future
arrhythmic events and sudden death in CAD patients (Grippo and
Johnson, 2002).Studies have suggested that depression may increase the risk
for cardiovascular morbidity and mortality through decreased
HRV, although mixed ﬁndings have been reported. While
depression has been associated with reduced HRV in cardiac
patients (Carney et al., 2001; Carney and Freedland, 2009; Stein
et al., 2000; Van den Berg et al., 2005), studies have also reported
on the absence of a relationship between HRV and depression
(Gehi et al., 2005; Martens et al., 2008). This contrasting
observation may in part be clariﬁed by the presence of different
symptoms in depressed, stable CAD and ACS patients. A recent
reanalysis of the data from Gehi and colleagues showed that
somatic symptoms of depression (such as fatigue and psychomotor
changes) were associated with reduced HRV while cognitive
symptoms (such as negative self-image) were not (De Jonge et al.,
2007a). Another explanation for this discrepancy could lie in the
timing of Holter monitoring as stable CAD and ACS patients
represent different phases in the continuum of the coronary
atherosclerotic process.
The possibility that the ANS might be implicated as a factor
underlying the association between depression and poor cardio-
vascular prognosis, is debated as on the one hand Carney et al.
(2005) report a partial mediation of the effect of depression on
mortality by low HRV, while on the other hand Kamphuis et al.
(2007) report that the increased risk of cardiovascular mortality
due to depression in the general population, was not affected by
HRV.
1.2. Inﬂammation
Inﬂammatory processes, such as leukocyte recruitment and
expression of pro-inﬂammatory cytokines, are considered to
contribute to the destabilization of atherosclerotic plaques and
induce rupture and thrombosis in the later stages of atherosclero-
sis (Ross, 1999). Inﬂammatory markers also participate in the
pathophysiology of CAD by direct effects on myocardial contrac-
tility and apoptosis, as was shown in patients with acute ACS
(Tousoulis et al., 2006). Levels of C-reactive protein (CRP),
interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha were
found to be higher in CAD patients, and these elevations impose an
increased risk of major adverse cardiac events and mortality
(Sukhija et al., 2007).
Depression is associated with increased levels of inﬂammation
(reﬂected in increased levels of inﬂammatory markers like CRP, IL-
6) in both CAD patients and psychiatric patients without CAD as
shown in a recent meta-analysis (Howren et al., 2009). In
psychiatric patients, pro-inﬂammatory cytokines have been
positively related to individual depressive symptoms such as
fatigue, cognitive dysfunction, and impaired sleep, as well as to an
increased risk of treatment resistance (Miller et al., in press).
Several studies have demonstrated that CAD patients with
depression, as compared to the non-depressed, are characterized
by an increased pro-inﬂammatory state (see Lett et al., 2004 for a
review). It is known that such a pro-inﬂammatory state may
induce ‘sickness-behavior’ in which somatic, ﬂu-like symptoms of
depression such as fatigue, anorexia and psychomotor retardation
dominate (Dantzer et al., 2008), potentially explaining (part of) the
relation between depression and inﬂammation.
Only a few studies have examined whether the effects of
depression on cardiac prognosis may be mediated by inﬂamma-
tion. Vaccarino et al. (2007) found that depressed women with
suspected ACS had an increased chance of adverse cardiac events
(i.e. hospital stays for nonfatal MI, stroke, CHF, and CAD-related
mortality) compared to their non-depressed counterparts. This
increased risk could only for a small part be explained by increased
levels of CRP and IL-6. Moreover, in patients with stable CAD, CRP
levels explained only a small part of the increased risk of adverse
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death) in those with depressive symptoms when considered in
concert with a broader range of potentially mediating factors
including behavioral ones (Whooley et al., 2008).
Endothelial dysfunction is one of the major features of the
pathogenesis atherosclerosis. A non-invasive index for Endothelial
function is the Flow mediated dilatation (FMD) of the brachial
artery. Using FMD endothelial function is found to be an
independent predictor of cadiovascular events in CAD patients.
Moreover, a lower FMD is found in depressed patients compared to
healthy controls. Additionally, in CAD patients depression was
independently associated with a lower FMD (Pizzi et al., 2008;
Sherwood et al., 2005), suggesting endothelial function to be a
mediator in the relation between depression and the risk for
cardiovascular events.
1.3. Platelet function
Platelets are involved in thrombus formation, a key pathophys-
iological mechanism in atherosclerosis and MI (Nemeroff and
Musselman, 2000), as activated platelets stimulate atherosclerotic
plaque progression, and anticoagulation therapy with platelet
antagonists has proven to prevent MI.
It has been suggested that depression may also be linked to
disturbed platelet function. A recent meta-analysis on the
potential role of platelet activity in the depression – CAD link
showed that several platelet activity markers are found to be
increased in depressed patients as compared to non-depressed
controls. In addition, studies that have compared depressed CAD
patients with non-depressed CAD patients generally show
increased levels of platelet releasing factors in CAD patients with
comorbid depression (e.g., Von Ka¨nel, 2004). In depression, plasma
serotonin (Wulsin et al., 2009) and norepinephrine levels (Wong
et al., 2004) are increased. Since serotonin and norepinephrine are
platelet agonists (Von Ka¨nel, 2004), higher levels of these
parameters will result in increased platelet activation through
positive feedback loops. It should be noted, however, that the
ﬁndings in this area of study are very diverse (Von Ka¨nel, 2004).
1.4. Hypothalamus–pituitary–adrenal axis
The HPA axis plays a pivotal role in the human stress response,
and its end product cortisol is heavily involved in the regulation of
normal physiology. HPA axis dysregulation is associated with a
variety of related CAD risk factors such as abdominal obesity,
hypercholesterolemia, hypertriglyceridemia, hypertension, and
glucose intolerance (Brown et al., 2004), although not all studies
have conﬁrmed these associations (Otte et al., 2004). Dysregulated
cortisol secretion has been observed in the context of CAD, and it
has been suggested that HPA axis dysfunction is implicated in the
pathogenesis of CAD (Nijm and Jonasson, 2009).
In major depression, or after continued exposure to stress, the
HPA axis is dysregulated in some cases, resulting either in a
chronically excessive secretion of cortisol, due to diminished
corticosteroid receptor sensitivity and a continuously increased
hypothalamic secretion of corticotrophin releasing hormone, in
the melancholic subtype, or in a chronically hypoactive HPA axis,
due to corticotrophin releasing hormone deﬁciency in atypical
major depression (Gold and Chrousos, 2002; Holsboer, 2001).
Although not formally tested, research ﬁndings hint at a
mediatory role for cortisol, as HPA axis dysregulation in depressed
patients affects a host of cardiovascular risk factors (Brown et al.,
2004) and HPA axis dysregulated has been implicated in the
pathogenesis of CAD (Nijm and Jonasson, 2009) and predicted CAD
death in depressed male CAD patients (Jokinen and Nordstro¨m,
2009). Further evidence comes from a study in which higher levelsof depressive symptoms were signiﬁcantly associated with an
increased prevalence of the metabolic syndrome, partially
mediated by HPA axis function, as reﬂected by urinary cortisol
levels (Vogelzangs et al., 2007). Besides its mediating role, cortisol
might be a shared risk factor for depression and CAD. Genetic
studies indicate that common polymorphisms associated with
altered HPA axis function might increase the risk of both
depression and CAD (Koeijvoets et al., 2008; Van Rossum et al.,
2006).
1.5. Serotonin
Serotonin modulates the formation of heart and brain already
early in embryogenesis (Nebigil et al., 2000). The cardiovascular
effects of serotonin are diverse; amongst them are brady- and
tachycardia, vasoconstriction and dilatation. Long-term exposure
to serotonin results in proliferative diseases of the endothelium
and thickening of the cardiac valves (Watts, 2005).
Central serotonin dysfunction is considered as one of the main
pathophysiological factors in depression, as serotonin metabolism
is disturbed (Bach-Mizrachi et al., 2008), and genetic variations in
proteins involved in serotonin processing have been associated to
depression (Lopez-Leon et al., 2008). Furthermore, disturbed
central serotonin transmission is associated with hypothalamic
abnormalities that may contribute to altered appetite, and
decreased libido, as well as thalamic and brainstem dysregulations
thought to contribute to altered sleep (Ressler and Nemeroff,
2000). These depression-related signs and symptoms may also be
observed in the onset of CAD.
Evidence supporting the role of serotonin in the association
between depression and CAD comes from genetic studies. A large
twin study revealed that shared genetic factors contribute
substantially to the co-variation of depression and CAD (McCaffery
et al., 2006). In another study, associations were found between
speciﬁc genetic variants of the serotonin transporter and the
presence of post-MI depression (Nakatani et al., 2005). Further
support comes from experimental studies reviewed in Van Melle
et al. (2006), showing that serotonin reuptake inhibitors, which
normalize serotonin transmission in the brain, may reduce activity
of platelets, decrease sympathetic nervous system activity, and
may induce vasodilatation in vitro. However, above ﬁndings are
preliminary, and by no means conclusive, as the methodological
quality of studies is not optimal, and results should be replicated in
vivo.
1.6. Polyunsaturated fatty acids
There are several distinct classes of PUFA, which are differenti-
ated by the location of the double bonds in the fatty acid carbon
chain. For example, omega-3 PUFAs have the ﬁrst double bond
after the third carbon atom, omega-6 PUFA after the 6th carbon
atom. PUFAs play an important role in cellular integrity and intra-
and intercellular signal transduction and have been linked to
cardiovascular health but also to mental health.
In CAD patients, the use of omega-3 fatty acid supplements has
been associated with a reduced risk of cardiac events and a
decrease in the progression of atherosclerosis (Kris-Etherton et al.,
2002). These protective effects of omega-3 fatty acids are explained
by their anti-inﬂammatory properties, via direct effects on
cytokine signal transduction and via control over the expression
of pro-inﬂammatory cytokines (Massaro et al., 2008). In addition,
omega-3 PUFAs have the potential to lower serum triglycerides
(Weber and Raederstorff, 2000), while the use of relatively high
doses of omega-3 PUFA (>3 g/day) has been found to be associated
with clinically relevant blood pressure reductions in individuals
with untreated hypertension (Appel et al., 1993).
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unclear, as there are many inconsistent ﬁndings. A meta-analysis
on the effects of the consumption of omega-3 PUFAs showed a
small beneﬁcial effect in patients diagnosed with major depres-
sion, whereas this effect was absent in subclinically depressed
populations (Appleton et al., 2006). In several small studies,
depression has been associated with a decreased presence of
omega-3 PUFA in adipose tissue, marking long-term dietary intake
of omega-3 fatty acids (Sarri et al., 2008;Mamalakis et al., 2006). In
addition, depression has been linked to lowered levels of omega-3
PUFA in erythrocyte membranes, a more short-term measure of
dietary intake of omega-3 PUFA, in case-control studies (Assies
et al., 2004; Edwards et al., 1998).
A couple of studies have examined omega-3 PUFA levels in CAD
patients with comorbid depression, showing that plasma levels
omega-3 PUFA were lower in currently depressed patients who
recently suffered an ACS (Frasure-Smith et al., 2004). Amin and
coworkers further showed that as compared to non-depressed CAD
patients, the depressed patients had lower omega-3 PUFA levels in
their erythrocyte membranes (Amin et al., 2008).
2. Integrating the psychophysiological factors
Given the fact that both depression and CAD are complex,
heterogeneous diseases, it is unlikely that a single psychophysio-
logical factor will explain a substantial proportion of the
prospective association between depression and cardiac outcome.
Accordingly, a recent review of the neurobiological mechanisms
underlying the association between stress, mood disorders and
cardiovascular dysregulation concluded that the bidirectional
association between mood disorders and heart disease is
multifaceted, involving an integration of several central and
peripheral processes (Grippo and Johnson, 2009).
Multiple lines of evidence support the presence of a network of
effects, of which serotonergic projection may be of speciﬁc
importance. Central serotonergic projections are involved in the
central regulation of cardiovascular reﬂexes and control both
parasympathetic and sympathetic cardiovascular drives (Ramage
and Villalon, 2008). These projections also modulate relevant
endocrine axes, including the HPA axis (Fuller, 1996). Peripheral
serotonin plays an established role in platelet aggregation and
activation, facilitating plaque and thrombus formation, and in the
regulation of vascular tone, hereby inducing hypertension, and
facilitating damage to the vascular walls (Jonnakuty and Gragnoli,
2008). Further, HPA axis hyperactivity inducing prolonged
exposure to high levels of cortisol results in several changes in
the immune system, such as the down-regulation of glucocorticoid
receptors on leukocytes, thereby nullifying cortisol’s natural
immunosuppressant effects, and contributing to the pro-inﬂam-
matory state that promotes atherosclerosis (Miller et al., 2002).
Atherosclerosis itself, due to its inﬂammatory properties, promotes
the catabolism of tryptophan, leading to a decrease in central
serotonin (Russo et al., 2003), as well as increased immune and
platelet activation. In addition, desensitisation of central glucocor-
ticoid receptors induces disturbances in central norepinephrine
and serotonin transmission (Leonard and Myint, 2009). Inﬂuence
of the HPA axis hyperactivity on serotonin also follows from
research showing that SSRI treatment for depression is less
effective in patients with a hyperactive HPA axis (Porter et al.,
2004). Associations between PUFAs and serotonin and inﬂamma-
tion have also been suggested, as omega-3 and omega-6 PUFAs
increase membrane ﬂuidity and inﬂuence serotonergic neuro-
transmission (Chalon, 2006). Further, omega-3 PUFAs inhibit the
production of pro-inﬂammatory cytokines by reducing the
production of pro-inﬂammatory prostaglandins (Calder, 2006).
Recent pre-clinical experimental evidence shows a complexbidirectional relation between the sympathetic nervous system
and inﬂammatory pathways. Peripheral pro-inﬂammatory cyto-
kines induce activation of afferent neurons of the vagus nerve and
central areas activating this nerve. The other way round the
cholinergic-anti-inﬂammatory pathway was found to inﬂuence
cytokine production of macrophages (Rosas-Ballina et al., 2009).
Moreover, in a clinical study HVR was inversely correlated with
inﬂammatory markers in both healthy individuals and CAD
patients (Haensel et al., 2008) suggesting a role of the
cholinergic-anti-inﬂammatory pathway in the pathophysiology
of CAD.
Although tempting to represent all these interrelations in a
single model, in our opinion, any attempt to develop such amodel
would fail, as it would be a priori incomplete, too succinct or too
complex and losing its illustrative meaning. The relation between
depression and CAD is best described as a complex system,
consisting of many distinct but interrelated and interdependent
components linked through multiple interconnections and
feedback loops. We can only observe properties in cardiac
patients with depression that emerge from the interaction of
these components, and cannot be predicted from the properties of
these individual components, as they are too much intertwined
(Whooley et al., 2008). Instead of the presently prevailing
reductionist approach in medical research, the entirety of
processes involved in the relation between depression and CAD
prognosis are better examined holistically, using advanced
computational models from system biology instead of regular
medical statistics. At the present, the inability of researchers to
address the interrelatedness of the psychophysiological factors
(using regular statistics) prevents the drawing of ﬁrm conclusions
on how the mediating mechanisms between depression and
cardiac events may operate.
In addition, although a thorough discussion of behavioral
mechanisms underlying the association is beyond the scope of this
review, recent evidence suggests that non-compliance to cardiac
aftercare and access to cardiac aftercare may be important
mediators which have been relatively understudied. Skala et al.
(2006) noted that physiological pathways have received far greater
attention thanbehavioral onesofwhichnon-optimalCADtreatment
(Druss et al., 2000), non-adherence to cardiac treatment (Ziegelstein
et al., 2000) and aftercare programs (Grace et al., 2005), and poor
lifestyle including smoking, poor diet, and limited physical activity
(Whooley et al., 2008) are the most plausible ones. Druss and
colleagues (Druss et al., 2000), comparing the health care utilization
of post-ACS patients with and without mental disorders, found that
patients with documented mood disorder were signiﬁcantly less
likely to undergo cardiovascular procedures. This ﬁnding suggests
that physician decision making process or physician-patient
interactions may result in suboptimal care for depressed ACS
patients. In addition, higher rates of non-adherence and drop-out
from CAD treatment regimens and aftercare programs have been
reported in depressed (post-ACS) patients (Grace et al., 2005).
Separate lines of research have indicated that depression is
associated with an increased risk of displaying behavior patterns
considered to be risk factors for CAD and its progression, including
smoking (Manley et al., 2009), lack of physical exercise (Babyak et
al., 2000) and being overweight (Lavie et al., 2009).
Strong recent evidence for the statement that lifestyle
represents an important pathway between depression and CAD
prognosis comes from the Heart and Soul study (Whooley et al.,
2008), in which lifestyle factors accounted for almost 50% of the
association between depression and new cardiac events. Physical
activity alone accounted for >30% of the effects. Interestingly,
physiological factors, including heart rate variability, inﬂammato-
ry markers and serotonin levels only mildly attenuated
the association between depression and cardiovascular events,
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research on the depression-heart disease association.
3. Clinical implications
It is yet not clear whether progress in the understanding of the
possible psychophysiological mechanisms will result in treatment
options that will lead to both depression beneﬁts and improved
cardiac outcome. Apparently, the effects of antidepressants
impacting on serotonin metabolism in CAD patients are compara-
ble to the effects in persons in the general population (Thombs et
al., 2008), in which a substantial proportion of depressive
symptoms disappear also in response to placebo treatment or
even in the absence of treatment. From a theoretical point of view,
SSRIs may have the potential to improve cardiovascular prognosis
(Van Melle et al., 2006). Depression is associated with enhanced
platelet reactivity. Interestingly, SSRIs have shown pleiotropic
effects. For example based on the level of platelet and endothelium
derived biomarkers sertraline exhibited antiplatelet and endothe-
lium protective properties (Serebruany et al., 2005). Animal
studies pointed to vasoactive properties of sertraline (Van Melle et
al., 2004a,b). It could therefore be hypothesized that in CAD
patients SSRIs have beneﬁcial effects independent from their CNS
antidepressant effect. Effects of SSRIs on platelet hyperactivity
seem quite consistent but may relate to an intrinsic pharmacologic
effect of SSRIs on platelet function independent of depression
(Galan et al., 2009). This is an important example to show that
there might be underlying third factors contributing to both
depression and CAD without the two necessarily being linked
causally with each other.
However, in practice the effects of SSRIs on psychophysiological
parameters are rather conﬂicting at best: the available studies are
small, contradictory and difﬁcult to compare due to differences in
inclusion criteria. The effects of SSRIs on HRV have been studied,
yet remain unclear: while some have found positive effects on HRV
(Balogh et al., 1993; Khaykin et al., 1998), others have found
negative effects (Volkers et al., 2004). No beneﬁcial effects of
antidepressant treatment on cardiac outcomes have been reported,
except for indirect evidence from non-randomised comparisons
(Taylor et al., 2005; De Jonge et al., 2007b). More, larger and
carefully designed studies are thereforewarranted, that in addition
to hard medical outcomes also examine the response of multiple
physiological characteristics to antidepressant therapy.
The extent to which depression can be regarded as a single
disease entity in the presence of a severe physical illness such as
CAD has been debated in the literature in recent years (e.g. De
Jonge and Ormel, 2008). While the diagnosis of depression is
determined on the basis of the presence of nine different
symptoms, consistent support for the observation that some
symptoms may be more strongly related to cardiac outcomes than
other can be found. Speciﬁcally, the distinction between somatic-
affective versus cognitive-affective has proved to be of interest, in
which the ﬁrst is consistently found to be associated with a
worsened prognosis than the latter (e.g. De Jonge et al., 2006;
Martens et al., 2009; Linke et al., 2009). Since it may be expected
that these different symptom dimensions may warrant different
therapeutical approaches, this distinction may be relevant for
optimising antidepressant treatments in the future.
4. Concluding remarks
Although the bidirectional association between depression and
cardiovascular disease is well documented, much of the role of
psychophysiological factors explaining this association remains
unclear due to the complexity of the network of systems involved.
More attention should be directed to integrating the variety offactors and assuming a more interdisciplinary approach, in which
an amalgamation is sought between psychophysiological and
behavioral factors.
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